Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases : A potential mimicker of residual disease after anti CD19 therapy
© 2024 International Clinical Cytometry Society..
CD19 is frequently targeted for immunotherapy in B cell malignancies, which may result in loss of CD19 expression in leukemic cells as an escape mechanism. Stage 0 hematogones (Hgs) are normal CD19-negative very early B cell precursors that can be potentially mistaken for CD19 negative residual leukemic cells by flow cytometry (FCM) in B cell acute lymphoblastic leukemia (BCP-ALL) cases treated with anti CD19 therapy. Our main objective was to characterize and study the incidence of stage 0 hematogones in follow-up bone marrow samples of pediatric BCP-ALL cases. We analyzed the flow cytometry standard files of 61 pediatric BCP-ALL cases treated with conventional chemotherapy and targeted anti-CD19 therapy, for identifying the residual disease and normal B cell precursors including stage 0 Hgs. A non-CD19 alternate gating strategy was used to isolate the B cells for detecting the residual disease and stage 0 Hgs. The stage 0 Hgs were seen in 95% of marrow samples containing CD19+ Hgs. When compared with controls and posttransplant marrow samples, the fraction of stage 0 Hgs was higher in patients receiving anti CD19 therapy (p = 0.0048), but it was not significant when compared with patients receiving chemotherapy (p = 0.1788). Isolated stage 0 Hgs are found in samples treated with anti-CD19 therapy simulating CD19 negative residual illness. Our findings aid in understanding the stage 0 Hgs and its association with CD19+ Hgs in anti CD19 therapy and conventional chemotherapy. This is crucial as it can be potentially mistaken for residual disease in patients treated with anti CD19 therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:106 |
|---|---|
| Enthalten in: |
Cytometry. Part B, Clinical cytometry - 106(2024), 2 vom: 05. März, Seite 92-98 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramalingam, Thulasi Raman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti‐CD19 therapy |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cyto.b.22159 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367341174 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367341174 | ||
| 003 | DE-627 | ||
| 005 | 20240408232245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cyto.b.22159 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM367341174 | ||
| 035 | |a (NLM)38243626 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramalingam, Thulasi Raman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases |b A potential mimicker of residual disease after anti CD19 therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 International Clinical Cytometry Society. | ||
| 520 | |a CD19 is frequently targeted for immunotherapy in B cell malignancies, which may result in loss of CD19 expression in leukemic cells as an escape mechanism. Stage 0 hematogones (Hgs) are normal CD19-negative very early B cell precursors that can be potentially mistaken for CD19 negative residual leukemic cells by flow cytometry (FCM) in B cell acute lymphoblastic leukemia (BCP-ALL) cases treated with anti CD19 therapy. Our main objective was to characterize and study the incidence of stage 0 hematogones in follow-up bone marrow samples of pediatric BCP-ALL cases. We analyzed the flow cytometry standard files of 61 pediatric BCP-ALL cases treated with conventional chemotherapy and targeted anti-CD19 therapy, for identifying the residual disease and normal B cell precursors including stage 0 Hgs. A non-CD19 alternate gating strategy was used to isolate the B cells for detecting the residual disease and stage 0 Hgs. The stage 0 Hgs were seen in 95% of marrow samples containing CD19+ Hgs. When compared with controls and posttransplant marrow samples, the fraction of stage 0 Hgs was higher in patients receiving anti CD19 therapy (p = 0.0048), but it was not significant when compared with patients receiving chemotherapy (p = 0.1788). Isolated stage 0 Hgs are found in samples treated with anti-CD19 therapy simulating CD19 negative residual illness. Our findings aid in understanding the stage 0 Hgs and its association with CD19+ Hgs in anti CD19 therapy and conventional chemotherapy. This is crucial as it can be potentially mistaken for residual disease in patients treated with anti CD19 therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD19‐negative B cell precursors | |
| 650 | 4 | |a anti‐CD19 therapy | |
| 650 | 4 | |a flow cytometry | |
| 650 | 4 | |a hematogones | |
| 650 | 4 | |a measurable residual disease | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 700 | 1 | |a Vaidhyanathan, Lakshman |e verfasserin |4 aut | |
| 700 | 1 | |a Muthu, Anurekha |e verfasserin |4 aut | |
| 700 | 1 | |a Swaminathan, Venkateswaran Vellaichamy |e verfasserin |4 aut | |
| 700 | 1 | |a Uppuluri, Ramya |e verfasserin |4 aut | |
| 700 | 1 | |a Raj, Revathi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytometry. Part B, Clinical cytometry |d 2003 |g 106(2024), 2 vom: 05. März, Seite 92-98 |w (DE-627)NLM122834577 |x 1552-4957 |7 nnns |
| 773 | 1 | 8 | |g volume:106 |g year:2024 |g number:2 |g day:05 |g month:03 |g pages:92-98 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cyto.b.22159 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 106 |j 2024 |e 2 |b 05 |c 03 |h 92-98 | ||